Quick Menu

Upcoming Journals
  • No Upcoming Journals

International Journal of Biochemistry Research & Review

International Journal of Biochemistry Research & Review, ISSN: 2231-086X,Vol.: 16, Issue.: 1

 

Original-research-article

 

Circulating Survivin and TIMP-1 in Hepatitis C Virus Associated Liver Fibrosis

 

 

Bakheet E. M. Elsadek1*, Ahmed A. Abdel Ghany1, Soad M. Abdel Ghany2, Shamardan E. S. Bazeed3, Mohamed A. Abdel Aziz1, Salama R. Abdel Raheim4 and Abdullatif A. Ahmed1

1Department of Biochemistry, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.

2Department of Medical Biochemistry, Faculty of Medicine, Assiut University, Egypt.

3Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, South Valley University, Qena, Egypt.

 4Department of Biochemistry, Faculty of Medicine, Minia University, Egypt.

 

Abstracts

 

Aims: The present study was conducted to assess the clinical utility of survivin, an anti-apoptotic protein, and the profibrogenic tissue inhibitor metalloproteinase-1 (TIMP-1) as non-invasive biomarkers for the discrimination between stages of HCV-associated liver fibrosis that are largely asymptomatic.

Methodology: Circulating survivin and TIMP-1 levels as well as their corresponding proteins and genes expressions were, respectively, assessed by ELISA, Western blot and RT-PCR in 100 HCV-infected patients at different stages of liver fibrosis in comparison to healthy controls.

Results: With the progression of hepatic fibrosis, each of circulating survivin and TIMP-1 as well as their ratio (survivin/TIMP-1) showed a stepwise increase and exhibited significant positive correlations with the fibrotic stage (r=0.98 & p=0.002, r=0.95 & p=0.01, and r=0.93 & p=0.013 respectively). A gradual increase in both survivin and TIMP-1 genes expression was also observed.

Conclusion: In conclusion, survivin, TIMP-1, and their ratio could represent promising biomarkers for prediction and discrimination of different stages of HCV-associated liver fibrosis. The higher sensitivity and specificity of survivin may provide new insights into its possible use as a target for the antifibrotic drugs. Further studies with validated tests on a large scale prospective clinical trial are required to ascertain these results.

 

Keywords :

urvivin; tissue inhibitor of metalloproteinase-1; liver fibrosis; hepatitis C virus.

 

Full Article - PDF    Supplementary Files    Page 1-13    Article Metrics

 

DOI : 10.9734/IJBCRR/2017/31609

Review History    Comments

Search this site

Advanced Search

Announcement & News

ISI Thomson Reuters selected British Journal of Pharmaceutical Research for Emerging Sources Citation Index

We are delighted to inform that ISI Thomson Reuters selected British Journal of Pharmaceutical Resea...

SCOPUS selected Annual Research & Review in Biology (ARRB)

We are delighted to inform that famous indexing organization SCOPUS (from Elsevier) selected  A...

Index Copernicus Evaluation Result Released

We are delighted to inform that Index Copernicus (a leading indexing organization from Pol...

Journal Repository (JR): Permanent Digital Archiving of SDI journals

SDI is happy to announce that all our journals are now permanently archived in Journal Repository (J...

Index Copernicus Value of British Journal of Medicine and Medical Research

  We are delighted to inform that Index Copernicus (a leading indexing organization ...

SDI journal got 35th ranking in Publons

We are delighted to announce (as of 04/01/2016) that British Journal of Medicine and Medical Re...

Growth of SDI and world publication market

As of 2014, total 25,064 journals are competing in World market of journal publication. In 2011, tot...

Publication and site statistics (up to Sept, 2015)

  Number of submission: 22181 (Total up to Sept, 2015) Number of published paper: 10949&n...

Index Medicus selected 15 SDI journals

We are delighted to inform that Index Medicus (IMSEAR) has selected following 15 SDI journals for in...

SCIENCEDOMAIN international received 5844 submissions in 2013

SCIENCEDOMAIN international is pleased to announce that it has received 5844 submissions in 2013, ac...



SCIENCEDOMAIN Awards

  • No Awards listed.

Browser Compatibility : Mozila firefox, Google Crome and IE 7 & above. Creative Commons License Terms & Condition   |   Privacy Policy   |   Join Us   |   Help   |   Contact Us
© Copyright 2010-2017, SCIENCEDOMAIN international. All rights reserved.